share_log

CRISPR Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer KASINGER JAMES R.

SEC announcement ·  Mar 12 17:49
Summary by Moomoo AI
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, engaged in multiple transactions involving the company's common stock between March 10, 2024, and March 12, 2024. Kasinger acquired a total of 7,750 shares through the exercise of derivative securities on March 10 and March 11. Subsequently, he sold 2,801 shares on March 11 at a price of $78.26 per share and 1,146 shares on March 12 at $74.44 per share, resulting in a total sale value of approximately $304,514.50. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics common stock amounted to 61,174 shares. The transactions are reported to be in progress.
James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, engaged in multiple transactions involving the company's common stock between March 10, 2024, and March 12, 2024. Kasinger acquired a total of 7,750 shares through the exercise of derivative securities on March 10 and March 11. Subsequently, he sold 2,801 shares on March 11 at a price of $78.26 per share and 1,146 shares on March 12 at $74.44 per share, resulting in a total sale value of approximately $304,514.50. Following these transactions, Kasinger's direct holdings in CRISPR Therapeutics common stock amounted to 61,174 shares. The transactions are reported to be in progress.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more